Navigation Links
More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
Date:10/30/2013

EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, while familiarity with FibroGen/Astellas/AstraZeneca's FG-4592/ASP1517 is low among surveyed nephrologists in the EU5 (France, Germany, Italy, Spain and the United Kingdom), close to one-half of EU5 nephrologists report a high interest in learning more about the product after reviewing a product profile. Surveyed EU5 nephrologists also indicate that 35 percent of their chronic kidney disease-non-dialysis patients and 28 percent of their dialysis patients are likely candidates for FG-4592/ASP1517, which is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in clinical development.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The report entitled TreatmentTrends®: Renal Anemia (EU5) 2013 also finds that Vifor Fresenius Medical Care (FMC) Renal Pharma's Venofer leads in reported patient share in the hemodialysis setting across the major European markets, followed by Sanofi's Ferrlecit / Ferlixit. Rockwell Medical's Triferic (soluble ferric pyrophosphate) is profiled in the report and 95 percent of surveyed nephrologists report low familiarity with this drug. 

The findings also reveal that over 90 percent of surveyed EU5 nephrologists report low familiarity with Keryx Biopharmaceuticals' Zerenex and Vifor Fresenius Medical Care's PA21.

"While Zerenex or PA21 are likely to reach the renal market before an oral HIF-PH inhibitor, if they do reach the market, HIF-PH inhibitors may be a disruptive change to the erythropoetin stimulating agent (ESA) marketplace," said BioTrends Research Group Director Rob Dubman. "In Germany, Italy and Spain, the study also found the use of ESA biosimilars is increasing as well, which is a more current market dynamic that will continue to impact branded ESAs in the near future."

TreatmentTrends®: Renal Anemia (EU5) 2013 is a syndicated report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia (ESAs, oral iron and IV iron) in patients with chronic kidney disease (stage 3, stage 4, peritoneal dialysis and hemodialysis). Topics include the percent of patients on each therapy, patient share, therapy initiation levels, perception of laboratory values, attribute importance and product performance ratings, sales representative metrics, transplant eligibility and reaction (familiarity, interest, and percentage of patients likely to be candidates) to new products in development. The 2013 wave published in October 2013 and is based on a study with 204 EU5 nephrologists.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
2. VirtualScopics Schedules Third Quarter 2013 Earnings Announcement
3. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
5. Hanger Reports Third Quarter 2013 Results
6. IGI Laboratories Announces Third Quarter 2013 Results
7. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
8. Questcor Reports Third Quarter Financial Results
9. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
10. Cynosure Reports Third-Quarter 2013 Financial Results
11. Genomic Health to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... GUIYANG, China , 23. Februar 2017 ... Area , eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz ... Beschleunigung der Errichtung einer Innovationsplattform aktiv an der Entwicklung einer ... Continue Reading ... ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
Breaking Medicine Technology:
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... The ... 2017 national conference convening academic faculty engaged in or interested in palliative care education ... Research,” will be held in North County San Diego on Sept. 28 and ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, ... a letter to withdraw previous guidance issued by the Obama Administration requiring ... issued in May 2016 by the Obama Administration came in response to a ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, ... be participating in Rare Disease Day events, hosted by the Rare Disease Legislative ... Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews with ...
Breaking Medicine News(10 mins):